1. Home
  2. SWTX vs PAY Comparison

SWTX vs PAY Comparison

Compare SWTX & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • PAY
  • Stock Information
  • Founded
  • SWTX 2017
  • PAY 2004
  • Country
  • SWTX United States
  • PAY United States
  • Employees
  • SWTX N/A
  • PAY N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • PAY Computer Software: Prepackaged Software
  • Sector
  • SWTX Health Care
  • PAY Technology
  • Exchange
  • SWTX Nasdaq
  • PAY Nasdaq
  • Market Cap
  • SWTX 3.5B
  • PAY 3.9B
  • IPO Year
  • SWTX 2019
  • PAY 2021
  • Fundamental
  • Price
  • SWTX $46.26
  • PAY $36.85
  • Analyst Decision
  • SWTX Buy
  • PAY Hold
  • Analyst Count
  • SWTX 7
  • PAY 5
  • Target Price
  • SWTX $56.86
  • PAY $35.60
  • AVG Volume (30 Days)
  • SWTX 8.7M
  • PAY 446.2K
  • Earning Date
  • SWTX 05-20-2025
  • PAY 05-05-2025
  • Dividend Yield
  • SWTX N/A
  • PAY N/A
  • EPS Growth
  • SWTX N/A
  • PAY 74.18
  • EPS
  • SWTX N/A
  • PAY 0.40
  • Revenue
  • SWTX $191,589,000.00
  • PAY $962,105,000.00
  • Revenue This Year
  • SWTX $86.36
  • PAY $24.00
  • Revenue Next Year
  • SWTX $69.02
  • PAY $19.80
  • P/E Ratio
  • SWTX N/A
  • PAY $92.11
  • Revenue Growth
  • SWTX 3417.33
  • PAY 47.78
  • 52 Week Low
  • SWTX $28.21
  • PAY $16.94
  • 52 Week High
  • SWTX $62.00
  • PAY $38.94
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 58.93
  • PAY 75.36
  • Support Level
  • SWTX $46.10
  • PAY $33.46
  • Resistance Level
  • SWTX $46.27
  • PAY $36.19
  • Average True Range (ATR)
  • SWTX 0.90
  • PAY 1.24
  • MACD
  • SWTX 0.58
  • PAY 0.54
  • Stochastic Oscillator
  • SWTX 99.46
  • PAY 93.88

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.

Share on Social Networks: